The Daily Folgen

When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.What is the story behind this new drug?Guest: Pam Belluck, a health and science writer for The New York Times.  Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter. Background reading: Aduhelm, also known as aducanumab, was approved despite opposition from the F.D.A.’s independent advisory committee and some Alzheimer’s experts.Even those who supported the F.D.A.’s approval have said that authorizing it for anyone with the disease is much too broad.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. Subscribe today at nytimes.com/podcasts or on Apple Podcasts, Spotify and Amazon Music. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Delta variant of the coronavirus is threatening to put the world in an entirely new stage of the pandemic.The variant is spreading fast, particularly in places with low vaccination rates — it is thought to be around 50 percent more transmissible than previous versions.What can be done to stop Delta, and how will the variant hamper global efforts to return to normalcy?Guest: Carl Zimmer, a science writer and author of the “Matter” column for The New York Times.Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter. Background reading: Vaccines are driving down coronavirus case numbers in the U.S., but it’s unclear whether Delta will reverse that trend. Here’s what scientists know about it.Conflicting advice from the health authorities about masks has bewildered a worried public.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. Subscribe today at nytimes.com/podcasts or on Apple Podcasts, Spotify and Amazon Music. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In Loudoun County, Va., a fierce debate has been raging for months inside normally sleepy school board meetings.At the heart of this anger is critical race theory, a once obscure academic framework for understanding racism in the United States.How, exactly, did critical race theory enter American public life, and what does this debate look like on the ground?Guest: Trip Gabriel, a national correspondent for The New York Times. Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter. Background reading: In a culture-war brawl that has spilled into the country’s education system, Republicans at the local, state and national levels are trying to block curriculums that emphasize systemic racism.More than 20 states have introduced legislation restricting lessons on racism and other so-called divisive concepts.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. Subscribe today at nytimes.com/podcasts or on Apple Podcasts, Spotify and Amazon Music. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.